Board of Directors
Scott Garland, MBA
Mr. Garland has served as a member of our board of directors since November 2014. Mr. Garland is currently President and Chief Executive Officer at Portola Pharmaceuticals, Inc. a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics targeting thrombosis and other hematologic diseases. Prior to joining Portola in 2018, Mr. Garland was President and previously Chief Commercial Officer at Relypsa Inc. Prior to Relypsa, Mr. Garland served as Executive Vice President and Chief Commercial Officer of Exelixis, Inc. a biopharmaceutical company focused on developing and commercializing cancer treatments, from October 2011 to October 2014. Prior to joining Exelixis, Mr. Garland spent close to a decade at Genentech leading the commercial franchises for two multi-billion dollar therapies – Avastin® (bevacizumab) and Rituxan® (rituximab). He started his career at Merck as a sales representative and then went on to serve at Amgen in various sales and marketing roles, including market development, to support the launch of Aranesp® (darbepoetin alfa). Mr. Garland has an M.B.A. from Duke University’s Fuqua School of Business and a B.A. from California Polytechnic University (San Luis Obispo).